Michael Barbella, Managing Editor03.11.21
The U.S. medical device industry experienced a flurry of deal activity in the final quarter of 2020.
According to GlobalData's deals database, the industry posted a 5.56 percent increase in cross-border deal activity compared with the last four-quarter average.
Led by Koninklijke Philips’ $2.8 billion acquisition of BioTelemetry, a total of 38 cross border deals worth $5.02 billion were announced in Q4 2020, compared with the last four-quarter average of 36 deals.
Venture financing was the leading category in the quarter (ended Dec. 31, 2020) with 24 cross border deals which accounted for 63.2 percent of all deals.
In second place was M&A with 12 deals, followed by private equity with two transactions, respectively accounting for 31.6 percent and 5.3 percent of overall cross border deal activity in the U.S. medical devices industry during the quarter.
In terms of value of cross border deals, M&A was the leading deal category in the U.S. medical devices industry with total deals worth $3.44 billion, while venture financing and private equity deals totalled $811.3 million and $770 million respectively.
The top five medical devices industry cross border deals accounted for 82.4 percent of the overall value during Q4 2020.
The combined value of the top five medical devices cross border deals stood at $4.14 billionn, against the overall value of $5.02 billion recorded for the quarter.
The top five medical devices industry cross border deals of Q4 2020 tracked by GlobalData were:
According to GlobalData's deals database, the industry posted a 5.56 percent increase in cross-border deal activity compared with the last four-quarter average.
Led by Koninklijke Philips’ $2.8 billion acquisition of BioTelemetry, a total of 38 cross border deals worth $5.02 billion were announced in Q4 2020, compared with the last four-quarter average of 36 deals.
Venture financing was the leading category in the quarter (ended Dec. 31, 2020) with 24 cross border deals which accounted for 63.2 percent of all deals.
In second place was M&A with 12 deals, followed by private equity with two transactions, respectively accounting for 31.6 percent and 5.3 percent of overall cross border deal activity in the U.S. medical devices industry during the quarter.
In terms of value of cross border deals, M&A was the leading deal category in the U.S. medical devices industry with total deals worth $3.44 billion, while venture financing and private equity deals totalled $811.3 million and $770 million respectively.
The top five medical devices industry cross border deals accounted for 82.4 percent of the overall value during Q4 2020.
The combined value of the top five medical devices cross border deals stood at $4.14 billionn, against the overall value of $5.02 billion recorded for the quarter.
The top five medical devices industry cross border deals of Q4 2020 tracked by GlobalData were:
- Koninklijke Philips’ $2.8 billion acquisition of BioTelemetry
- The $700 million private equity deal with Verily Life Sciences by Alphabet, Ontario Teachers’ Pension Plan, Silver Lake Partners and Temasek Holdings (private)
- AnGes’ $250 million acquisition of EmendoBio
- The $200 million venture financing deal with Tempus Labs by Baillie Gifford, Franklin Templeton Investments, Google, Novo Holdings, and T. Rowe Price Associates
- Weihai Weigao Shengrui Health Technology’s acquisition of Wego Healthcare Fund Holding for $188.13 million.
